Identifying and validating pre-clinical biomarkers for diagnostics and therapeutics of Neuromuscular Disorders
FP7 Project with U.S. partner
Short name and number
The rapidly expanding knowledge of NMDs genetic diagnosis, pathogenesis and therapeutic possibilities has provided new targets for disease characterisation, early diagnosis, drug discovery and development as well as has raised many questions about how to translate this knowledge into clinical practice as (initial) clinical trials typically run for such a short time that clinical improvement can hardly be expected within that time frame.
France, Germany, Sweden, The Netherlands and United States.
Name of US Partner
Ariadne Genomics Inc
UNIVERSITA DEGLI STUDI DI FERRARA (IT)